Acumen Pharmaceuticals to present at Bank of America 2026 Health Care Conference on May 14.

Acumen Pharmaceuticals, a clinical-stage biotech company focused on Alzheimer's disease treatments, will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The company is advancing its lead drug candidate, sabirnetug (ACU193), in a Phase 2 trial targeting early symptomatic Alzheimer's patients. This event provides an opportunity for investors to hear updates on their progress and future plans. The webcast will be available live and archived for 90 days on Acumen's website.